Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Todd M. Bauer, Julien Mazieres, Anna Polli, Benjamin Solomon, Enriqueta Felip, Gerson Peltz, Alice T. Shaw, Filippo de Marinis, Tony Mok, Geoffrey Liu, Yasushi Goto, A.M. Calella, Holger Thurm, Dong Wan Kim
Publikováno v:
Future Oncology. 17:4649-4656
This is a summary of a research study (known as a clinical trial) called CROWN. The study tested two medicines called lorlatinib and crizotinib in participants with untreated non-small cell lung cancer that had spread to other parts of their body. Al
Autor:
Filippo de Marinis, Helano C. Freitas, Yi-Long Wu, David Vicente, Gee-Chen Chang, Mariano Provencio, Nicolaas A. Bakker, J. Rigas, Sang We Kim, Qing Zhou, Liyan Jiang, Parneet Cheema, Gilberto de Castro, Claudio Martin, Giulio Metro, Byoung Chul Cho, Miguel F. Miranda, Johan Vansteenkiste, Yuh Min Chen
Publikováno v:
Future Oncology. 15:3003-3014
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior
Autor:
Filippo de Marinis, Catherine Dubos-Arvis, Pablo Perez-Moreno, Enric Carcereny, Ali Zeaiter, Alain Vergnenegre, Antonio Passaro, Rafael Rosell, Ana Drozdowskyj
Publikováno v:
Future Oncology. 11:421-429
ABSTRACT Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycle